Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Why now
Thesis: Micro-cap obesity drug pipeline update
Catalyst to watch: Phase 1 trial initiation
Main risk: Early-stage programs often fail
Why it matters
A small biotech's fiscal results and early-stage obesity program update matter only to its own equity.
Details
Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-28 11:30 UTC